Tumor Markers
Over the past 2-3 decades, an incredible amount of research has been done on breast cancer. One of the most important breakthroughs was discovering that most breast cancer is sensitive to estrogen. This has led to the development of medications that block estrogen. Your breast cancer pathology report will state whether your cancer is estrogen receptor-positive (ER+) or estrogen receptor-negative (ER-).
Breast cancer can also be sensitive to progesterone. This is also reported as progesterone receptor positive (PR+) or negative (PR-). This also factors into our treatment plan; however, it does not have as much impact as the estrogen receptor status.
Another critical tumor marker is referred to as HER2/NEU. This is reported as positive/amplified or negative/not amplified; HER2+ or HER2-.
This growth factor receptor is found in some breast cancer cells. Breast cancers that are HER2+ are treated with a particular chemotherapy regimen. Some of the most challenging breast cancers to treat are HER2+. A lot of current research is focused on this specific type of cancer.
We use the phrase triple-negative breast cancer (TNBC) to describe a subset of breast cancers that are negative for all three tumor markers. This type of breast cancer tends to be more aggressive, and these women are often given chemotherapy before surgery. Breakthroughs in research have led to some excellent outcomes in recent years in patients with TNBC.
The phrase triple positive breast cancer refers to cancer that is ER+, PR+, and HER2+. Inflammatory breast cancer (IBC) is, fortunately, very uncommon. Patients with IBC receive intense care from each specialist caring for them. The surgeon, the medical oncologist, and the radiation oncologist will communicate the timing of surgery, chemotherapy, and radiation for all cancers. Our treatment plans are based on several factors, as breast cancer care is individualized based on these tumor markers and risk factors to optimize patient outcomes.